SEC Form 4 · accession 0001651844-18-000005
NYMOX PHARMACEUTICAL CORP · NYMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James George Robinson
Director
Period of report
Feb 8, 2018
Accepted (ET)
Feb 9, 2018 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001018735
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 8, 2018 | P | 500 | $3.28 | A | 3,091,050 | D | |
| Common Stock | Feb 8, 2018 | P | 1,400 | $3.29 | A | 3,092,450 | D | |
| Common Stock | Feb 8, 2018 | P | 100 | $3.30 | A | 3,092,550 | D | |
| Common Stock | Feb 8, 2018 | P | 600 | $3.31 | A | 3,093,150 | D | |
| Common Stock | Feb 8, 2018 | P | 1,000 | $3.35 | A | 3,094,150 | D | |
| Common Stock | Feb 8, 2018 | P | 900 | $3.36 | A | 3,095,050 | D | |
| Common Stock | Feb 8, 2018 | P | 500 | $3.37 | A | 3,095,550 | D | |
| Common Stock | Feb 8, 2018 | P | 100 | $3.38 | A | 3,095,650 | D | |
| Common Stock | Feb 8, 2018 | P | 4,900 | $3.42 | A | 3,100,550 | D |
Table II — derivative securities
No Table II lines on this filing.